Why US Banned Transfer Of Genetic Samples To China

The FDA halted a program allowing the transfer of U.S. citizens' biological samples to China and other hostile nations, citing biosecurity concerns. Experts warn of the potential for this data to be used in biological warfare targeting specific populations. China's advanced genetic research capabilities and low handling costs made its facilities attractive for sample transfer. The FDA's review will examine clinical trials sending cells abroad, sometimes without patient knowledge or consent. Loopholes in data security rules allowed this transfer, despite a previous administration's exemption. This action, while impacting U.S.-China collaborations, is crucial for national security and data privacy. China's DNA collection is seen as an asymmetric warfare tactic, leveraging biological vulnerabilities. Recent arrests of Chinese researchers attempting to smuggle pathogens highlight the threat. The FDA's review is a first step; stricter regulations and comprehensive oversight are needed to prevent future incidents. The BIOSECURE Act further aims to limit China's access to sensitive U.S. biological data.